Uncategorized E-Clinical Solutions Market size worth $ 16.5 Billion, Globally, by 2028 at 12.4% CAGR: Verified Market Research® – Yahoo Finance

The increasing expenditure on clinical research and development in the pharmaceutical and biotechnology industry, the growing number of clinical trials, also rising need for improved data standardization, are the factors driving the market.
JERSEY CITY, N.J., Jan. 19, 2022 /PRNewswire/ — Verified Market Research recently published a report, "E-Clinical Solutions Market" By Type (Clinical Data Management System, Randomization and Trial Supply Management, Electronic Clinical Outcome Assessment), By Delivery Mode (Web-Based and Cloud-Based, Enterprise-Based), and By Geography. According to Verified Market Research, the Global E-Clinical Solutions Market size was valued at USD 6.5 Billion in 2020 and is projected to reach USD 16.5 Billion by 2028, growing at a CAGR of 12.4% from 2021 to 2028.
Download PDF Brochure:
Browse in-depth TOC on "E-Clinical Solutions Market"
202 – Pages
126 – Tables
37 – Figures
Global E-Clinical Solutions Market Overview
The attempts to invent treatments for numerous diseases, such as diabetes, cancer, and AIDS, are leading to increased spending by pharmaceutical, life sciences, clinical research, and biopharmaceutical firms, which is further driving the growth of the E-Clinical Solutions Market. The rising prevalence of chronic and lifestyle-related disorders, as well as the growing elderly population, are some factors propelling the E-Clinical Solutions Market forward.
As a result, the number of pharmaceuticals in development is increasing, which is leading to an increase in clinical trials. Countries such as China, India, and Poland have become popular locations for clinical trials among pharmaceutical companies in order to have a large pool of patients and reduce costs. However, the E-Clinical Solutions Market is being restrained by factors such as a long approval time for clinical trials, a lack of broadband facilities and IT specialists in rural locations, expensive implementation costs, and less-skilled manpower. Although e-clinical solutions are expensive, CROs, healthcare providers, and pharmaceutical and biotechnology companies are hesitant to utilize the technology.
The drug development process necessitates a significant financial investment, which is increased by the implementation of software, making it difficult for healthcare professionals to afford, restraining the growth of the E-Clinical Solutions Market. Furthermore, the increasing adoption of cloud technology for the development of e-clinical suits and the growing clinical research in emerging economies provide opportunities for players looking to invest in the E-Clinical Solutions Market.
Key Developments
In January 2021 – Bioclinica, a provider of integrated clinical life science and technology solutions, announced a collaboration with IKCON PHARMA to deliver best-in-class eClinical solutions to the pharmaceutical industry/sponsors.
In November 2020 – Signant Health acquired VirTrial, a leading provider of software solutions for remote site startup and decentralised clinical trial administration.
Key Players
The major players in the market are OmniComm Systems Inc, ERT, BioClinica, CRF Health Inc, DATATRAK International Inc, Medidata Solutions, Oracle Corporation, and PAREXEL International Corporation.
Verified Market Research has segmented the Global E-Clinical Solutions Market On the basis of Type, Delivery Mode, and Geography.
E-Clinical Solutions Market, By Type
E-Clinical Solutions Market, By Delivery Mode
E-Clinical Solutions Market by Geography
Browse Related Reports:
Augmented And Virtual Reality In Healthcare Market By End User (Government and Defense Institutions, Hospitals, Clinics, and Surgical Centers, Research and Diagnostics Laboratories), By Offerings (Software, Hardware), By Devices Types (Projectors and Display Walls, Virtual Reality in Healthcare Market), By Application (Patient Care Management, Surgery, Medical Training and Education), By Geography, Forecast, 2021-2028
Healthcare Cold Chain Logistics Market By Product Type (Vaccines, Clinical trial materials), By Services (Storage, Transportation), By Storage Techniques (Electrical refrigeration, Dry ice), By End-User (Biopharmaceutical companies, Hospitals and clinics), By Geography, Forecast, 2021-2028
U.S. Non-Acute Care Revenue Cycle Management Market By Products (Integrated and Standalone RCM), By Deployment (On-Premises, and Cloud-Based), By End-Use (Long-term Care, General Physician Clinics, Surgery Centers), By Geography, Forecast, 2021-2028
DNA And RNA Banking Services Market By Service (Transportation Service, Processing Service, Storage Service), By Specimen Type (Blood, Saliva), By Applications (Therapeutics, Drug Discovery & Clinical Research, Clinical Diagnostics), By End User (Hospitals & Diagnostic Centers, Academic Research, Pharmaceutical & Biotechnology Companies), By Geography, Forecast, 2021-2028
Top Clinical Trial Supplies focusing on safety of drugs
Visualize E-Clinical Solutions Market using Verified Market Intelligence:-:
Verified Market Intelligence is our BI Enabled Platform for narrative storytelling of this market. VMI offers in-depth forecasted trends and accurate Insights on over 20,000+ emerging & niche markets, helping you make critical revenue impacting decisions for a brilliant future.
VMI provides a holistic overview and global competitive landscape with respect to Region, Country, and Segment, and Key players of your market. Present your Market Report & findings with an inbuilt presentation feature saving over 70% of your time and resources for Investor, Sales & Marketing, R&D, and Product Development pitches. VMI enables data delivery In Excel and Interactive PDF formats with over 15+ Key Market Indicators for your market.
About Us
Verified Market Research is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals and critical revenue decisions.
Our 250 Analysts and SME's offer a high level of expertise in data collection and governance use industrial techniques to collect and analyze data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise and years of collective experience to produce informative and accurate research.
We study 14+ categories from Semiconductor & Electronics, Chemicals, Advanced Materials, Aerospace & Defense, Energy & Power, Healthcare, Pharmaceuticals, Automotive & Transportation, Information & Communication Technology, Software & Services, Information Security, Mining, Minerals & Metals, Building & construction, Agriculture industry and Medical Devices from over 100 countries.
Contact Us
Mr. Edwyne Fernandes
Verified Market Research®
US: +1 (650)-781-4080
UK: +44 (753)-715-0008
APAC: +61 (488)-85-9400
US Toll Free: +1 (800)-782-1768
Follow Us: LinkedIn | Twitter
View original content:–16-5-billion-globally-by-2028-at-12-4-cagr-verified-market-research-301463790.html
SOURCE Verified Market Research
Despite sell-offs roiling the broader market, the stock of Digital World Acquisition (NASDAQ: DWAC) is rocketing higher today. There doesn't appear to be any fresh news powering the gains, but excitement surrounding the stock is surging ahead of the company's merger with Trump Media & Technology Group and the launch of their social media platform, Truth Social. It's a social media service backed by Donald Trump that's on track to launch Feb. 21, and investors are pouring into Digital World Acquisition stock ahead of the debut.
The cut doesn't mean the business is in trouble, and AT&T's payout will still provide a solid passive income. AT&T has a pending deal to spin off WarnerMedia, AT&T's streaming and entertainment assets, and merge them with Discovery to form a stand-alone, new streaming company. AT&T shareholders will receive 71% of the shares of this new business, and shareholders of Discovery (also the proposed name of the new company) will receive the other 29%.
For the past 12 years, growth stocks have shone brightly on Wall Street. Below are five growth stocks with all the tools and catalysts necessary to make you richer in 2022 (and likely well beyond). The first fast-paced stock with the potential to drive home solid gains for investors throughout 2022 is electric vehicle (EV) manufacturer Nio (NYSE: NIO).
Let’s talk about quality stocks. Of course, this is the direction that every investor wants to go; but the question is, how to recognize them? Do we go all-in on the big-value, big-name giants? Or do we dig a little deeper, and find the high-end nuggets that are hiding in the sandheap? Weighing in from investment bank Morgan Stanley, chief investment officer Lisa Shalett recommends the latter. She recommends investors to look for beaten-down stocks, equities that have lost value recently – but t
In a somewhat counterintuitive development, shares of Axsome Therapeutics (NASDAQ: AXSM) rose on Thursday even though the company pointed out several issues in the development of one of its drugs. Following the company's latest update on the affected program, one analyst reiterated his bullish outlook on the shares, and they rose by 5.5%. In a regulatory filing, Axsome said it provided an official response to the Food and Drug Administration (FDA) regarding the pending New Drug Application (NDA) its AXS-05 drug candidate.
With the expected explosion of data coming over the next several years, these two stocks could benefit immensely.
The stock market isn't the right place for New Year's resolutions. Always focus on the long term for the best results.
If pre-market trading volumes are any indication, the Nasdaq could hit this low point as soon as this morning.
Volatility seems to be rising in the U.S. stock market lately. Yet even with its muted results, Caterpillar is still generating sizable profits and raking in plenty of free cash flow (FCF) to support its dividend thanks to high oil and gas prices, demand for raw materials, a healthy residential construction market, and an improving commercial construction market.
Business is booming for these life science businesses, but their stock prices have been slashed to bargain prices.
The streaming TV specialist continues to rapid grow its revenue and subscriber numbers, much to the delight of shareholders.
When interest rates increase, here's what historically has happened to the stock market.
In this article, we discuss the 10 Jim Cramer stocks to buy in Q1 2022. If you want to skip our detailed analysis of these stocks, go directly to the 5 Jim Cramer Stocks to Buy in Q1 2022. Investors have been scrambling to identify the “real value” of stocks as reports suggest that as […]
A look at the shareholders of General Electric Company ( NYSE:GE ) can tell us which group is most powerful…
Shares of Romeo Power (NYSE: RMO) are sinking amid a day of sell-offs for the broader market. In addition to bearish pressures impacting the market, Romeo Power stock also seems to be losing ground due to a recently announced change for its management team. Romeo Power's recent press release stated that Anne Devine will take over the COO position roughly a month from today.
Bank of America delivered strong fourth-quarter earnings Wednesday, bucking a trend seen across much of the sector this earnings season. Revenue of $22.1 billion was slightly lower than analysts’ forecasts but  was 10% higher than the fourth quarter of 2020. Despite the slight miss on sales, there was a lot like in Bank of America’s (ticker: BAC) numbers, especially in light of a challenging earnings season for the banks, which saw peers such as JPMorgan Chase (JPM) dogged by higher expenses and Goldman Sachs (GS) posting a rare miss on earnings Tuesday.
If we strictly looked at the performance of the major U.S. stock indexes, 2021 was a great year. While no investor enjoys seeing their stocks go in reverse, patience has a way of paying off handsomely in the stock market. In 2022, the following trio of turnaround stocks have the catalysts needed to bounce back in a big way.
Dame Emma Walmsley's campaign to reignite growth at GlaxoSmithKline by focusing on cutting-edge drug research has suffered a heavy blow with the resignation of Hal Barron, the superstar scientist she headhunted and paid more than herself.
GameStop could be hurt by Microsoft spending $68.7 billion to buy Activision Blizzard.
Procter & Gamble Co. shares rose 0.8% in Wednesday premarket trading after the consumer products company reported fiscal second quarter results that beat expectations and narrowed its full-year sales guidance. Net income totaled $4.22 billion, or $1.66 per share, up from $3.85 billion, or $1.47 per share, last year. Sales of $20.95 billion were up from $19.75 billion last year. The FactSet consensus was for EPS of $1.65 and sales of $20.34 billion. "These results keep us on track to deliver our


Author Details

Sign up for our newsletter to stay up to
date with tech news!